COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression - Positive topline results validated by additional analyses - Patient improvements beyond reduction of depression symptoms - Further insights into timing and circumstance of adverse...